New treatments better than standard ones just over half the time
Medicalnewstoday: 8/29/13 USF Distinguished Professor Benjamin Djulbegovic, MD, PhD, has studied the ethics of randomized clinical trials and their effectiveness in evaluating the outcomes of new treatments for decades. Now, in a paper published in the top journal Nature, Dr. Djulbegovic and colleagues report that on average new treatments work better than existing ones just over […]
Comparative Mortality Risk in Adult Patients With Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, and Attention-Deficit/Hyperactivity Disorder Participating in Psychopharmacology Clinical Trials
Importance There is concern that increased mortality risk among patients with psychiatric illness may be worsened by psychopharmacological agents. Objectives To assess mortality risk among adult patients with a diagnosis of schizophrenia, depression, bipolar disorder, anxiety disorders, or attention-deficit/hyperactivity disorder participating in clinical trials conducted by pharmaceutical companies for US Food and Drug Administration (FDA) […]
